Interferon alfa-2a in the treatment of cutaneous T cell lymphoma

Olsen, Elise A.; Rosen, Steven T.; Vollmer, Robin T.; Variakojis, Daina; Roenigk, Henry H.; Diab, Nagwa; Zeffren, J.

doi:10.1016/s0190-9622(89)70049-9

Cited by 216 publications

(102 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 A dose-related flu-like syndrome is the most common reason for discontinuation, and the cause of doselimiting toxicity. 55,56 This side-effect is observed in most patients but is alleviated by dose reduction. 56,57…”

Section: Interferon (Ifn)-amentioning

confidence: 99%

“…Olsen and colleagues treated 22 patients with IFN-a and observed CRs in 6 patients, with a CR rate of 27% and an ORR of 64%. 55 CRs were observed in patients with early (I-IIA) and advanced disease (IVA); all but 3 patients had received prior therapy. Ross and colleagues reviewed the results of IFN-a treatment in 304 patients with CTCL and reported that the ORR, including CRs, PRs and minor responses, was 70%.…”

Section: Topical Bcnumentioning

confidence: 99%

“…In the study by Olsen and colleagues, referred to earlier, responses were observed in 2 of 3 patients with stage III disease. 55 12.4.1.3. MTX.…”

Section: Retinoids Plus Puva Thomsen and Colleagues Re-mentioning

confidence: 99%

See 2 more Smart Citations

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

390

308

View full text Add to dashboard Cite

Section: Interferon (Ifn)-amentioning

confidence: 99%

Section: Topical Bcnumentioning

confidence: 99%

See 1 more Smart Citation

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

390

308

View full text Add to dashboard Cite

“…Interferon-alpha (i.e., interferon-alpha 2b), a type I interferon with immunomodulatory properties, has pleiotropic effects in CTCL and is associated with an overall response rate of 50-70% and a complete response rate of 20-30%, particularly in patients with limited-stage disease [285][286][287][288]. While often considered as second-line therapy for limitedstage CTCL, interferon-alpha, frequently at doses ranging from 3 to 10 million units daily to three times weekly, is a treatment to be considered in the first-line setting in patients with advanced-stage disease.…”

Section: Interferon-alphamentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

“…[51][52][53] Time to response is in the order of weeks, and it can be combined with PUVA, chemotherapy, retinoids, and bexarotene. 30,31,41,42,46,50,54,55 In advanced-stage disease, our preference is to use single-agent IFN-␣ first, adding PUVA if there is more widespread pruritus and adding bexarotene if the response is suboptimal.…”

Section: Ifn-␣ and Related Biologic Response Modifiersmentioning

confidence: 99%

How I treat mycosis fungoides and Sézary syndrome

Prince

Whittaker

Hoppe

2009

Blood

136

109

View full text Add to dashboard Cite

The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority of patients have indolent disease; and given the incurable nature of MF/SS, management should focus on improving symptoms and cosmesis while limiting toxicity. Management of MF/SS should use a “stage-based” approach; treatment of early-stage disease (IA-IIA) typically involves skin directed therapies that include topical corticosteroids, phototherapy (psoralen plus ultraviolet A radiation or ultraviolet B radiation), topical chemotherapy, topical or systemic bexarotene, and radiotherapy. Systemic approaches are used for recalcitrant early-stage disease, advanced-stage disease (IIB-IV), and transformed disease and include retinoids, such as bexarotene, interferon-α, histone deacetylase inhibitors, the fusion toxin denileukin diftitox, systemic chemotherapy including transplantation, and extracorporeal photopheresis. Examples of drugs under active investigation include new histone deacetylase inhibitors, forodesine, monoclonal antibodies, proteasome inhibitors, and immunomodulatory agents, such as lenalidomide. It is appropriate to consider patients for novel agents within clinical trials if they have failed front-line therapy and before chemotherapy is used.

show abstract

Interferon alfa-2a in the treatment of cutaneous T cell lymphoma

Cited by 216 publications

References 42 publications

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

How I treat mycosis fungoides and Sézary syndrome

Contact Info

Product

Resources

About